What's Happening?
City of Hope, a leading cancer research and treatment organization, is collaborating with Quest Diagnostics to evaluate the Haystack MRD test for managing patients with various cancers. The test, which uses circulating-tumor DNA (ctDNA) to detect minimal
residual disease, will be implemented in clinical trials across 14 City of Hope sites in the U.S. The research aims to assess the test's ability to detect residual disease, monitor treatment response, and identify cancer recurrence earlier than traditional imaging methods. This collaboration is expected to involve approximately 500 patients and generate significant data on the test's efficacy in guiding treatment decisions for breast, colorectal, ovarian, and prostate cancers.
Why It's Important?
The use of ctDNA-based MRD testing represents a significant advancement in oncology, offering the potential to detect cancer recurrence earlier than conventional methods. This early detection can lead to more timely interventions, potentially improving patient outcomes and reducing the need for aggressive treatments like chemotherapy. The collaboration between City of Hope and Quest Diagnostics could pave the way for broader adoption of liquid biopsy technologies in cancer care, influencing treatment protocols and healthcare policies. The research findings may also support the development of new diagnostic tools and therapeutic strategies, benefiting both patients and healthcare providers.
